CT of the liver and spleen with EOE-13: review of 225 examinations
- 1 August 1984
- journal article
- research article
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 143 (2), 235-243
- https://doi.org/10.2214/ajr.143.2.235
Abstract
EOE-13 is an experimental liver-spleen-specific computed tomographic (CT) contrast agent developed at the National Institutes of Health. Experience with this agent in 225 clinical examinations is described. On average, use of EOE-13 increases the attenuation of normal liver by 32.5 H and that of normal spleen by 52.3 H. Tumors in these organs increase only 2.6 H, making them more easily detectable. Most of the iodine in EOE-13 appears to clear from the liver and spleen by 24 hr after injection. No deaths or permanent morbidity have been observed. The complication rate is 3.6%. EOE-13 is valuable for the detection of hepatic and splenic tumors.Keywords
This publication has 6 references indexed in Scilit:
- Ethiodized oil emulsion 13 in computed tomography of hepatoma.Journal of Clinical Oncology, 1984
- Biodistribution Study of Ethiodized Oil Emulsion 13 for Computed Tomography of the Liver and SpleenJournal of Computer Assisted Tomography, 1982
- CT Detection of Hepatic Metastases with Ethiodized Oil Emulsion 13Journal of Computer Assisted Tomography, 1982
- Use of Liposoluble Contrast Material to Separate Left Renal and Splenic Parenchyma on Computed TomographyJournal of Computer Assisted Tomography, 1980
- Development and Experimental Evaluation of a Contrast Medium for Computed Tomographic Examination of the Liver and SpleenJournal of Computer Assisted Tomography, 1979
- Intravenous HepatosplenographyRadiology, 1976